时间的馈赠。 作者/王露 这也许是打工人最喜欢看到的一幕。 A股上市公司联影医疗发布公告称，公司五大员工持股平台合计减持股份1 3 3 7万股，总 价值高达1 8 . 2亿元。 回 望 2 0 11 年 ， 薛 敏 和 张 强 两 位 校 友 在 上 海 创 立 联 影 医 疗 ， 怀 揣 打 破 外 资 垄 断 的 初 心 ， 十 年 磨 一 剑 填 补 了 国 产 高 端 医 疗 装 备 的 空 白 。 2 0 2 2 年 公 司 成 功 登 陆 科 创 板 ， 如 今 市 值 约11 0 0亿。 行 至 当 下 ， 一 批 " 打 工 人 " 站 到 财 富 兑 现 的 聚 光 灯 。 这 是 一 场 关 于 耐 心 与 信 任 的 时 代 叙 事。 18亿，核心员工落袋 具体来看这笔减持——联影医疗的五家员工持股平台宁波影聚、宁波影力、宁波影健、 宁 波 影 康 及 上 海 影 董 ， 通 过 集 中 竞 价 及 大 宗 交 易 方 式 减 持 公 司 股 份 ， 持 股 数 量 减 少 约 1 3 3 7万股，总金额为1 8 . 2亿元。 这一幕，早在十多年前就埋下了种子。 自 2 0 1 3 年 ...

这也许是打工人最喜欢看到的一幕。 A股上市公司联影医疗发布公告称，公司五大员工持股平台合计减持股份1337万股，总价值高达18.2亿 元。 回望2011年，薛敏和张强两位校友在上海创立联影医疗，怀揣打破外资垄断的初心，十年磨一剑填补了 国产高端医疗装备的空白。2022年公司成功登陆科创板，如今市值约1100亿。 行至当下，一批"打工人"站到财富兑现的聚光灯。这是一场关于耐心与信任的时代叙事。 18亿，核心员工落袋 具体来看这笔减持联影医疗的五家员工持股平台宁波影聚、宁波影力、宁波影健、宁波影康及上海影 董，通过集中竞价及大宗交易方式减持公司股份，持股数量减少约1337万股，总金额为18.2亿元。 这一幕，早在十多年前就埋下了种子。 自2013年开始，联影医疗为了激励员工，通过董事会下设"薪酬委员会"向核心人才发放虚拟股份。此 后，公司又将原有的虚拟股计划调整为员工持股计划。 为配合这一安排，联影医疗在2017年搭建起五家员工持股平台即本次减持主体。上述平台的执行事务合 伙人均由公司董事长兼联席首席执行官张强担任。 公告显示，联影医疗的员工持股计划已覆盖800余名受益人，主体为在岗雇员及曾对公司做出突出贡献 的 ...

WESTBROOK, ME - JANUARY 4: IDEXX Laboratories has been added to the Standard & Poor's 500 Index. (Photo by Ben McCanna/Portland Portland Press Herald via Getty Images)Portland Press Herald via Getty ImagesIDEXX Laboratories’ (IDXX) recent jump has investors questioning whether it’s still the best bet—or if a stronger opportunity exists elsewhere. A closer look at its key competitor suggests there may be a clearer winner. IDXX stock rose by 5.3% over the past day. You might feel inclined to purchase addition ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688626 证券简称：翔宇医疗公告编号：2025-056 河南翔宇医疗设备股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一）股东大会召开的时间：2025年11月24日 （二）股东大会召开的地点：河南省安阳市内黄县帝喾大道中段公司会议室 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： ■ 注：公司表决权数量不含截至股权登记日公司已回购股份的数量。 （四）表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，由董事长何永正先生主持，会议以现场投票和网络投票相结合的方式 进行表决。本次会议的召集、召开及表决方式符合《公司法》、《证券法》、《公司章程》等的规定。 （五）公司董事、监事和董事会秘书的出席情况 1、公司在任董事5人，现场出席5人； 2、公司在任监事 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、股东大会审议通过本次权益分派基本情况 1、公司于2025年11月20日召开2025年第二次临时股东大会审议通过了关于《公司2025年前三季度利润 分配方案》的议案。股东大会决议公告刊登于2025年11月21日的《证券时报》《上海证券报》和巨潮资 讯网（www.cninfo.com.cn）。 2、自分配方案披露至实施期间公司的股本总额未发生变化。 3、本次实施的分配方案与股东大会审议通过的分配方案一致，按照分配比例不变的原则。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002223 证券简称：鱼跃医疗 公告编号：2025-047 江苏鱼跃医疗设备股份有限公司 2025年前三季度权益分派实施公告 四、本次权益分派对象 4、本次实施分配方案距离股东大会审议通过的时间未超过两个月。 本次分派对象为：截至2025年12月1日下午深圳证券交易所收市后，在中国证券登记结算有限责任公司 深圳分公司（以下简称"中国结算深圳分公司"）登记在册的本公司全体股东。 二、本次权益分派方案 五、权益分派方法 本公司20 ...

Group 1 - Huafeng Co., Ltd. announced a stock suspension due to a potential change in control after signing a share transfer intention agreement [1] - Keshida plans to reduce its shareholding by up to 424,000 shares, representing 0.07% of its total share capital [1] - Jinqilin intends to distribute a cash dividend of 0.10 yuan per share, totaling 19.61 million yuan [1] Group 2 - Rejingshi Biotech has repurchased 904,100 shares, accounting for 0.98% of its total share capital, with a total expenditure of 150 million yuan [2] - Yishitong has repurchased 1,236,500 shares, representing 0.619% of its total share capital, with a total expenditure of approximately 33.49 million yuan [2] Group 3 - Hanjia Design announced the release of a detention on its subsidiary's chairman, allowing him to resume duties [4] - Qingmu Technology plans to acquire 65.83% of Vitalis Pharma AS for 300 million Norwegian Krone (approximately 212 million yuan) [4] - Anda Intelligent's shareholder plans to reduce its stake by up to 2.74% [4] Group 4 - Wansheng Intelligent is a candidate for a project with a pre-bid amount of approximately 42.99 million yuan, representing 4.56% of its audited revenue for 2024 [4] - Yipin Hong received a drug registration certificate for a medication used to treat Alzheimer's symptoms [4] Group 5 - *ST Sansheng received a total of 254 million yuan from restructuring investors [4] - Haichuang Pharmaceutical received approval for clinical trials of HP518 tablets for advanced prostate cancer treatment [4] Group 6 - Ningbo Huaxiang's subsidiary plans to invest 5 million yuan in a venture capital fund focusing on intelligent industries [4] - Petty Co. plans to repurchase shares worth 50 to 70 million yuan [4] Group 7 - Tongji Technology's subsidiary won a construction project with a bid price of 866 million yuan [4] - Prolo Pharmaceutical received a drug registration certificate for a generic drug [4] Group 8 - Jingyan Technology plans to use up to 1.6 billion yuan of idle funds for financial management [4] - Furan De received government subsidies totaling 34.65 million yuan [4] Group 9 - David Medical's subsidiary's medical device registration has been accepted [4] - Jusaylong plans to increase its subsidiary's capital by 170 million yuan through debt-to-equity conversion [4] Group 10 - Heng Rui Pharmaceutical's application for a drug license has been accepted by the National Medical Products Administration [4] - Lege Co. plans to increase its stake in the company by 40 to 80 million yuan [4] Group 11 - New Beiyang's subsidiary won a project with the Bank of Communications [4] - Jiangxi Changyun plans to publicly transfer land use rights and buildings with a starting price of 7.79 million yuan [4] Group 12 - Shenqi Pharmaceutical's subsidiary has paid approximately 16.67 million yuan in tax and penalties [4] - Panjiang Co. plans to invest 1.334 billion yuan in a power plant project [4] Group 13 - Fashilong's vice president resigned for personal reasons [4] - Chunxue Food received government subsidies of 3.79 million yuan [4] Group 14 - China Galaxy completed the repayment of a short-term financing bond totaling 3.025 billion yuan [4] - Jiuzhou Pharmaceutical received approval for a chemical raw material drug [4] Group 15 - Longqi Technology's subsidiary plans to invest 30 million yuan in a venture capital fund [4]

支付体系与产业生态共建是规模化关键 "从临床上来讲，AI也好、大模型也好，始终是一个手段、一个技术。最终要回到临床，技术到底能解 决临床什么问题？"在11月21日举办的2025华夏大健康产业发展暨康复服务大会上，歌锐科技高级副总 裁兼产品创新总经理刘建勋在圆桌对话中分享了公司在AI医疗设备领域的前沿实践与深刻思考。 本次大会以"智领健康未来"为主题，在《AI医疗的规模化破局：从技术爆发到医疗价值兑现》圆桌环 节，刘建勋与迪安诊断、赛诺医疗、医脉通等企业代表共同探讨了AI技术在医疗领域的发展路径。 歌锐科技作为一家成立不到五年，专注于领先技术创新的创新企业，公司产品线覆盖微创外科、血管介 入、肿瘤介入、康养和护理，目前已在骨科领域取得突破性进展，其全球首创的全电动一体化术中三维 影像系统已经面市，"牛顿"骨科内窥镜手术机器人进行了数百例的活体动物和大体实验后，已经进入多 中心人体临床试验阶段，即将上市。 临床价值是AI医疗创新的根本导向 刘建勋在对话中强调，技术创新必须始终以解决临床实际问题为出发点。"在AI医疗产品落地过程中， 核心是要回归临床本质。只有紧扣临床需求，技术创新才能真正创造价值。"这一理念已深度 ...

将投中网设为"星标⭐"，第一时间收获最新推送 获奖名单揭晓，落地转化全面启动。 来源丨 投中网 2025 年 11 月 21 日，由兰溪资本主办，投中信息、兰溪市人才集团协办的"首届兰溪创新创业大赛总决赛"在浙江兰溪成功举办。 作为" 2025 兰溪 科创投资大会"的核心环节，大赛的顺利举行标志着为期两天的系列活动圆满收官。本次活动吸引了来自全国各地的创新企业踊跃参与，通过"以赛引 才"精准对接兰溪" 1+4+X "现代产业体系，集中展现了兰溪在集聚科创资源、培育新兴产业方面的积极姿态。 12 强项目同台竞技，硬科技赛道亮点纷呈 经过前期全国海选与线上半决赛的层层选拔， 12 个优质项目成功晋级总决赛，覆盖具身智能、高速光通信、激光精密制造、氢能装备、 RISC-V 芯 片、医疗器件、半导体封装、碳捕集技术等前沿领域，充分体现出科技创新与产业升级的深度融合。 决赛现场，参赛团队通过" 12 分钟路演 + 评委问答"形式，全面展示项目技术优势与落地潜力。由创东方、创景资本、达晨财智、复星锐正、光合创 投、海尔资本、华睿投资、汇芯投资、普华资本、启航创投、浙商创投等十余家一线投资机构合伙人组成的评审团，从技术壁垒 ...

Core Viewpoint - Beijing Ruimait Medical Technology Co., Ltd. is experiencing positive market movement, with a recent stock increase of 1.49% and a total market capitalization of 8.673 billion yuan, driven by its focus on respiratory health medical devices and favorable currency conditions [1][2]. Company Overview - The company specializes in manufacturing medical devices and consumables in the respiratory health sector, including various types of sleep apnea machines and monitoring devices [2][7]. - As of September 30, the company reported a revenue of 808 million yuan for the first nine months of 2025, reflecting a year-on-year growth of 34.24%, and a net profit of 180 million yuan, up 43.87% [8]. Financial Performance - The overseas revenue contribution is significant, accounting for 64.21% of total revenue, benefiting from the depreciation of the yuan [3]. - The company has distributed a total of 228 million yuan in dividends since its A-share listing [8]. Shareholder and Market Activity - As of September 30, the number of shareholders increased by 16.36% to 7,971, while the average circulating shares per person decreased by 14.20% [8]. - The stock has seen a net inflow of 2.0224 million yuan from major investors, indicating a growing interest in the stock despite a lack of clear trends in major fund movements [4][5]. Technical Analysis - The average trading cost of the stock is 88.45 yuan, with current price action suggesting a trading range between resistance at 97.44 yuan and support at 95.40 yuan, indicating potential for short-term trading strategies [6].

Core Viewpoint - Tianzhihang's stock price has experienced a decline recently, despite a significant increase in its stock price year-to-date, indicating potential volatility in the market [1][2]. Company Overview - Tianzhihang Medical Technology Co., Ltd. specializes in the research, production, sales, and service of orthopedic surgical navigation robots, with a revenue composition of 58.31% from navigation robots, 23.86% from supporting equipment and consumables, 16.49% from technical services, and 1.31% from other sources [1]. - The company was established on October 22, 2010, and went public on July 7, 2020 [1]. Financial Performance - For the period from January to September 2025, Tianzhihang reported a revenue of 187 million yuan, representing a year-on-year growth of 103.51%. However, the net profit attributable to shareholders was -114 million yuan, a decrease of 49.73% compared to the previous year [2]. - The stock price has increased by 55.26% year-to-date, but has seen declines of 8.76% over the last five trading days, 12.22% over the last twenty days, and 22.18% over the last sixty days [1]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders increased by 12.31% to 17,300, with an average of 26,094 shares held per shareholder, a decrease of 10.96% [2]. - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on February 17, where it recorded a net purchase of 26.27 million yuan [1]. Market Position - Tianzhihang is categorized under the pharmaceutical and biological industry, specifically in medical devices, and is associated with concepts such as robotics, specialized innovation, and medical equipment [2].